Tesamorelin and BPC-157 are two of the most clinically studied peptides available through Viking Alternative Medicine. Tesamorelin is FDA-approved; BPC-157 has strong preclinical evidence but remains investigational. This guide explains what each does, who benefits, and how they compare.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release natural growth hormone (GH) in a pulsatile pattern — mimicking physiologic GH secretion. It was FDA-approved in 2010 (brand name Egrifta) for HIV-related lipodystrophy and is used off-label for body composition and cognitive function in men 40+.
Tesamorelin Mechanism
Tesamorelin binds GHRH receptors → pituitary releases GH → liver produces IGF-1 → downstream anabolic and metabolic effects. Unlike direct HGH injections, tesamorelin preserves normal GH pulsatility and negative feedback — reducing side effect risk.
Tesamorelin Clinical Evidence
Body composition (RCT, n=412): 2.5mg/day × 26 weeks → 15-20% reduction in visceral adipose tissue (VAT), sustained at 52 weeks. No effect on subcutaneous fat — specifically targets abdominal visceral fat.
Cognitive function (TEAAM trial, n=152, men 60-65): Improved executive function and verbal memory vs placebo at 12 months. Benefits most pronounced in men with mild cognitive decline at baseline.
IGF-1 increase: Average 80-100 ng/mL increase from baseline. Viking requires IGF-1 monitoring every 3 months on protocol.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protective protein in gastric juice. It is NOT FDA-approved and is classified as a research peptide. Viking offers it for investigational use only. Clinical interest centers on its remarkable tissue repair and anti-inflammatory properties.
BPC-157 Mechanism
BPC-157 acts via multiple pathways: upregulation of growth hormone receptor expression, promotion of VEGF (vascular endothelial growth factor) for angiogenesis, activation of nitric oxide synthesis, and modulation of dopamine/serotonin systems. Uniquely, it appears to work whether administered orally, subcutaneously, or intraperitoneally — suggesting systemic activity.
BPC-157 Preclinical Evidence
All published BPC-157 research is animal-based (rats, mice). No peer-reviewed human RCTs exist as of 2026. Preclinical data shows:
- Accelerated tendon-to-bone healing (torn rotator cuff models)
- Improved muscle repair after crush injury
- Gut healing in NSAID-induced ulcer models
- Nerve regeneration after sciatic nerve transection
- Reduced inflammation in inflammatory bowel disease models
- Neuroprotective effects in traumatic brain injury models
Tesamorelin vs BPC-157: Side-by-Side Comparison
| Feature | Tesamorelin | BPC-157 |
|---|---|---|
| FDA Status | Approved (Egrifta) | Not approved / investigational |
| Evidence Level | Phase 3 RCTs in humans | Animal studies only |
| Primary Mechanism | GHRH receptor → pituitary GH release | Multi-pathway: VEGF, NO, GHR upregulation |
| Main Use Cases | Visceral fat reduction, cognitive function, anti-aging | Tendon/muscle repair, gut healing, neuroprotection |
| Administration | Subcutaneous injection (2.5mg/day or 2mg/night) | Subcutaneous injection (250-500mcg/day) or oral |
| Monitoring Required | IGF-1 every 3 months, glucose, HbA1c | No established monitoring protocol |
| Viking Availability | Yes (prescribed by physician) | Yes (investigational use, physician consult) |
| Contraindications | Active malignancy, pregnancy, pituitary tumor | Unknown (no human safety data) |
Who Should Consider Tesamorelin?
Tesamorelin is most appropriate for men who:
- Have visible abdominal fat accumulation (visceral adiposity) not responding to diet/exercise
- Are already on TRT and want to optimize body composition further
- Experience cognitive decline, memory issues, or executive function slowing
- Are 45+ and want evidence-based anti-aging intervention
- Have adequate baseline IGF-1 (ideally 150-250 ng/mL before adding tesamorelin)
Who Should Consider BPC-157?
BPC-157 is most appropriate for men who:
- Have chronic tendon or joint injuries (rotator cuff, Achilles, elbow tendinopathy)
- Have gut issues (IBS, leaky gut, NSAID damage) that aren’t resolving
- Are willing to accept investigational status in exchange for potential accelerated recovery
- Are already stable on TRT and want a targeted repair tool
Can You Stack Tesamorelin and BPC-157?
Yes. Many Viking patients run both simultaneously. There is no known interaction between them. A common protocol: tesamorelin 2mg before sleep (nightly, 3-5 months on/2 months off) + BPC-157 250-500mcg daily during active injury recovery. The two peptides address different systems — GH axis optimization vs tissue repair — making them complementary rather than redundant.
Viking Alternative Medicine Peptide Program
Viking prescribes peptides through licensed physicians in almost every state. Every peptide patient gets baseline labs, a physician consultation, and ongoing monitoring. Tesamorelin is available as a standard prescription; BPC-157 is offered through Viking’s investigational peptide program after physician review.
Initial consultation: Schedule at vikingalternative.com. Peptide-specific labs included in the assessment.
Recent Comments